Why Merit Medical Systems stock is in focus after the Splashwire recall
Merit Medical Systems (MMSI) is drawing attention after a voluntary Class II recall of over 5,000 Splashwire Hydrophilic Guide Wire units. The development is raising questions about quality controls, customer relationships, and any knock on effects for product availability.
See our latest analysis for Merit Medical Systems.
Merit Medical Systems' share price has recently been under pressure, with the year to date share price return down 17.8% and the 1 year total shareholder return down 26%. At the same time, the 30 day share price return of 7.6% points to some short term momentum around recent news, including the Splashwire recall and a recent shelf registration filing.
If this recall has you reassessing your healthcare exposure, it could be a good moment to look at other specialist opportunities in the sector through our screener of 40 healthcare AI stocks.
For Merit Medical Systems, a 7.6% rebound over 30 days after a recall and an ESOP shelf filing can look like improving confidence or simply sentiment swinging off a weak base. How does that square with the current valuation setup?
Most Popular Narrative: 20.6% Undervalued
The most followed valuation narrative currently places Merit Medical Systems' fair value at $89.55 versus a last close of $71.06, framing the recent share price weakness against a higher intrinsic value estimate.
Ongoing investments in operational efficiency, manufacturing automation, and product portfolio expansion through innovation and strategic M&A are driving improved gross and operating margins (evidenced by record 21% non-GAAP operating margin), supporting higher cash flow and net earnings.
Want to see what sits behind that margin story and the projected earnings climb, revenue cadence, and future multiple that underpin the $89.55 fair value? The core narrative leans on specific growth rates, a defined profit step up, and a premium P/E that all have to work together for this valuation to hold.
Result: Fair Value of $89.55 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that margin story for Merit Medical Systems still hinges on smoother WRAPSODY CIE reimbursement and manageable tariffs and China pricing pressure, both of which could unsettle the current narrative.
Find out about the key risks to this Merit Medical Systems narrative.
Another View: Merit Medical Systems Through a P/E Lens
The DCF narrative frames Merit Medical Systems as trading below an estimated fair value of $103.68, yet the current P/E of 30.4x sits above both the US Medical Equipment industry at 26.8x and an internal fair ratio of 23.2x. That mix of discount and premium raises an important question: where is the valuation risk or opportunity greatest for you?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed sentiment around Merit Medical Systems has you torn, it makes sense to act promptly and evaluate the potential benefits yourself using the 4 key rewards.
Looking for more investment ideas beyond Merit Medical Systems?
Consider extending your research beyond Merit Medical Systems and broadening your watchlist with other focused stock ideas that draw on different strengths across the market.
- Explore potential income opportunities by scanning for companies with resilient payouts and higher yields using the 9 dividend fortresses.
- Search for quality at a reasonable price by reviewing the 44 high quality undervalued stocks, which highlights companies that combine solid fundamentals with attractive pricing.
- Emphasise resilience by using the 72 resilient stocks with low risk scores to find companies with steadier profiles and lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com